General Information of Drug Transporter (DT)
DT ID DTD0003 Transporter Info
Gene Name ABCB1
Transporter Name P-glycoprotein 1
Gene ID
5243
UniProt ID
P08183
Exogenous Factors (drugs, dietary constituents, etc.) Modulating DT Activity (EFMDA)
Exogenous Factor Cyclosporine Approved Drug
DT Modulation Cyclosporine inhibits the transportation of Calcein AM by ABCB1 (Ki = 4.66 microM) [1]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Cyclosporine inhibits the transportation of Calcein AM by ABCB1 (Ki = 1.8 microM) [2]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System CEM/VLB100 drug-resistant cells-MDR1
DT Modulation Cyclosporine inhibits the transportation of Calcein AM by ABCB1 (IC50 = 3.41 microM) [3]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System CEM/VLB100 drug-resistant cells-MDR1
DT Modulation Cyclosporine inhibits the transportation of Calcein AM by ABCB1 (IC50 = 1.7 microM) [4]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Cyclosporine inhibits the transportation of Calcein AM by ABCB1 (IC50 = 0.8 microM) [5]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Cyclosporine inhibits the transportation of Colchicine by ABCB1 (IC50 = 1.36 microM) [6]
Affected Drug/Substrate Colchicine Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Cyclosporine inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 1.4 microM) [4]
Affected Drug/Substrate Daunorubicin Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Cyclosporine inhibits the transportation of Digoxin by ABCB1 (Ki = 0.46 microM) [7]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Cyclosporine inhibits the transportation of Digoxin by ABCB1 (Ki = 0.35 +/- 0.04 microM) [8]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Cyclosporine inhibits the transportation of Digoxin by ABCB1 (IC50 = 1.6 microM) [6]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Cyclosporine inhibits the transportation of Digoxin by ABCB1 (IC50 = 1.3 microM) [9]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Cyclosporine inhibits the transportation of Doxorubicin by ABCB1 (IC50 = 3.66 microM) [10]
Affected Drug/Substrate Doxorubicin Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Cyclosporine inhibits the transportation of Fluo-3-AM by ABCB1 (IC50 = 2.4 microM) [4]
Affected Drug/Substrate Fluo-3-AM Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Cyclosporine inhibits the transportation of LDS-751 by ABCB1 (IC50 = 1.8 microM) [4]
Affected Drug/Substrate LDS-751 Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Cyclosporine inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 1.7 microM) [4]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Cyclosporine inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 1.4 microM) [11]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Cyclosporine inhibits the transportation of Tetramethylrosamine by ABCB1 (IC50 = 2.1 microM) [4]
Affected Drug/Substrate Tetramethylrosamine Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Cyclosporine inhibits the transportation of Verapamil by ABCB1 (Ki = 0.02 microM) [12]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Cell System Spodoptera frugiperda (Sf9) cells-MDR1
DT Modulation Cyclosporine inhibits the transportation of Vinblastine by ABCB1 (IC50 = 6.18 microM) [6]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Cyclosporine inhibits the transportation of Vinblastine by ABCB1 (Ki = 1.3 microM) [1]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Cyclosporine inhibits the transportation of Calcein AM by ABCB1 [13], [14]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System Doxorubicin resistant A2780adr cell lines-MDR1
DT Modulation Cyclosporine inhibits the transportation of Colchicine by ABCB1 [15]
Affected Drug/Substrate Colchicine Modulation Type Inhibition
Cell System Human T-cell line (CEM)/Tumour cell line-MDR1
DT Modulation Cyclosporine inhibits the transportation of Doxorubicin by ABCB1 [16]
Affected Drug/Substrate Doxorubicin Modulation Type Inhibition
Cell System Myelogenous leukemia cell line (K562)-MDR1
DT Modulation Cyclosporine inhibits the transportation of Imatinib by ABCB1 [17]
Affected Drug/Substrate Imatinib Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Cyclosporine inhibits the transportation of Indinavir by ABCB1 [18]
Affected Drug/Substrate Indinavir Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Cyclosporine inhibits the transportation of Propranolol by ABCB1 [19]
Affected Drug/Substrate Propranolol Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Cyclosporine inhibits the transportation of Rhodamine 123 by ABCB1 [20]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Human ileocecal adenocarcinoma cell lines (HCT-8)-MDR1
DT Modulation Cyclosporine inhibits the transportation of Rhodamine 123 by ABCB1 [21]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Mouse T-lymphoma L5178-MDR1
DT Modulation Cyclosporine inhibits the transportation of Saquinavir by ABCB1 [20]
Affected Drug/Substrate Saquinavir Modulation Type Inhibition
Cell System Human ileocecal adenocarcinoma cell lines (HCT-8)-MDR1
DT Modulation Cyclosporine inhibits the transportation of Saquinavir by ABCB1 [22]
Affected Drug/Substrate Saquinavir Modulation Type Inhibition
Cell System LLC-PK1 porcine kidney epithelial (LLC-GA5-COL150) cells-MDR1
DT Modulation Cyclosporine inhibits the transportation of JC-1 by ABCB1 [23]
Affected Drug/Substrate JC-1 Modulation Type Inhibition
DT Modulation Cyclosporine inhibits the transportation of Vinblastine by ABCB1 [24]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
DT Modulation Cyclosporine inhibits the activity of ABCB1 [25]
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Cyclosporine induces the activity of ABCB1 [26], [27]
Exogenous Factor Verapamil Approved Drug
DT Modulation Verapamil inhibits the transportation of Colchicine by ABCB1 (IC50 = 17.3 microM) [6]
Affected Drug/Substrate Colchicine Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Verapamil inhibits the transportation of Digoxin by ABCB1 (Ki = 15.1 microM) [7]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Madin-Darby Canine Kidney (MDCK) cells-MDR1
DT Modulation Verapamil inhibits the transportation of Digoxin by ABCB1 (Ki = 8.11 microM) [7]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Verapamil inhibits the transportation of Digoxin by ABCB1 (IC50 = 10.7 microM) [6]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Verapamil inhibits the transportation of Fexofenadine by ABCB1 (IC50 = 8.44 microM) [28]
Affected Drug/Substrate Fexofenadine Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Verapamil inhibits the transportation of Irinotecan by ABCB1 (Ki = 29 microM) [29]
Affected Drug/Substrate Irinotecan Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Verapamil inhibits the transportation of Paclitaxel by ABCB1 (IC50 = 4.78 microM) [30]
Affected Drug/Substrate Paclitaxel Modulation Type Inhibition
Cell System Human uterine cancer cells (MES-SA/Dx5)
DT Modulation Verapamil inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 4.2 microM) [11]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Verapamil inhibits the transportation of Vinblastine by ABCB1 (IC50 = 33.5 microM) [6]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Verapamil inhibits the transportation of Vincristine by ABCB1 (IC50 = 0.2 microM) [31]
Affected Drug/Substrate Vincristine Modulation Type Inhibition
Cell System Myelogenous leukemia cell line (K562)-MDR1
DT Modulation Verapamil inhibits the transportation of Paclitaxel by ABCB1 (IC50 = 2.21 microM) [30]
Affected Drug/Substrate Paclitaxel Modulation Type Inhibition
DT Modulation Verapamil inhibits the transportation of Calcein by ABCB1 [32]
Affected Drug/Substrate Calcein Modulation Type Inhibition
Cell System Adriamycin-Resistant Human Ovarian Cancer A2780 cells-MDR1
DT Modulation Verapamil inhibits the transportation of Calcein AM by ABCB1 [33]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System Human colon cancer cell lines (HCT-15)-MDR1
DT Modulation Verapamil inhibits the transportation of Daunomycin by ABCB1 [34]
Affected Drug/Substrate Daunomycin Modulation Type Inhibition
Cell System NIH 3T3 cells-MDR1
DT Modulation Verapamil inhibits the transportation of Digoxin by ABCB1 [35]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Verapamil inhibits the transportation of Rhodamine 123 by ABCB1 [36]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Madin-Darby Canine Kidney (MDCK) cells-MDR1
DT Modulation Verapamil inhibits the transportation of Adriamycin by ABCB1 [37], [38], [39]
Affected Drug/Substrate Adriamycin Modulation Type Inhibition
DT Modulation Verapamil inhibits the transportation of Doxorubicin by ABCB1 [40], [39]
Affected Drug/Substrate Doxorubicin Modulation Type Inhibition
DT Modulation Verapamil inhibits the activity of ABCB1 [41], [40]
Exogenous Factor Valspodar Discontinued Drug
DT Modulation Valspodar inhibits the transportation of Digoxin by ABCB1 (IC50 = 0.11 microM) [9]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Valspodar inhibits the transportation of Digoxin by ABCB1 (IC50 = 0.0222 microM) [42]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Valspodar inhibits the transportation of Doxorubicin by ABCB1 (IC50 = 0.291 microM) [10]
Affected Drug/Substrate Doxorubicin Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Valspodar inhibits the transportation of Vinblastine by ABCB1 (IC50 = 1.06 microM) [10]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Valspodar inhibits the transportation of Calcein AM by ABCB1 (Ki = 1.3 microM) [2]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
DT Modulation Valspodar inhibits the transportation of Verapamil by ABCB1 (Ki = 0.134 microM) [43]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
DT Modulation Valspodar inhibits the transportation of Cyclosporin A by ABCB1 [44]
Affected Drug/Substrate Cyclosporine A Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Valspodar inhibits the transportation of Indinavir by ABCB1 [45]
Affected Drug/Substrate Indinavir Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Valspodar inhibits the transportation of Iodoaryl-azidoprazosin by ABCB1 [46]
Affected Drug/Substrate Iodoaryl-azidoprazosin Modulation Type Inhibition
Cell System CEM/VLB100 drug-resistant cells-MDR1
DT Modulation Valspodar inhibits the transportation of mitoxantrone by ABCB1 [47]
Affected Drug/Substrate mitoxantrone Modulation Type Inhibition
Cell System Human breast adenocarcinoma cell line (MCF-7)-MDR1
DT Modulation Valspodar inhibits the transportation of Nelfinavir by ABCB1 [45]
Affected Drug/Substrate Nelfinavir Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Valspodar inhibits the transportation of Saquinavir by ABCB1 [45]
Affected Drug/Substrate Saquinavir Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Valspodar inhibits the transportation of Calcein AM by ABCB1 [48]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Exogenous Factor Quinine Approved Drug
DT Modulation Quinine inhibits the transportation of Colchicine by ABCB1 (IC50 = 51.7 microM) [6]
Affected Drug/Substrate Colchicine Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Quinine inhibits the transportation of Digoxin by ABCB1 (Ki = 8.59 microM) [7]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Madin-Darby Canine Kidney (MDCK) cells-MDR1
DT Modulation Quinine inhibits the transportation of Digoxin by ABCB1 (Ki = 3.23 microM) [7]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Quinine inhibits the transportation of Digoxin by ABCB1 (IC50 = 22.4 microM) [49]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Quinine inhibits the transportation of Digoxin by ABCB1 (IC50 = 14.9 microM) [6]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Quinine inhibits the transportation of Digoxin by ABCB1 (IC50 = 9.52 microM) [50]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Quinine inhibits the transportation of Digoxin by ABCB1 (IC50 = 9.4 microM) [49]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Quinine inhibits the transportation of Vinblastine by ABCB1 (IC50 = 22.9 microM) [6]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Quinine inhibits the transportation of Rhodamine 123 by ABCB1 [21]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Mouse T-lymphoma L5178-MDR1
Exogenous Factor Elacridar Discontinued Drug
DT Modulation Elacridar inhibits the transportation of Colchicine by ABCB1 (IC50 = 0.027 microM) [6]
Affected Drug/Substrate Colchicine Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Elacridar inhibits the transportation of Digoxin by ABCB1 (Ki = 0.44 microM) [7]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Madin-Darby Canine Kidney (MDCK) cells-MDR1
DT Modulation Elacridar inhibits the transportation of Digoxin by ABCB1 (Ki = 0.39 microM) [7]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Elacridar inhibits the transportation of Digoxin by ABCB1 (IC50 = 0.18 microM) [49]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Elacridar inhibits the transportation of Digoxin by ABCB1 (IC50 = 0.055 microM) [6]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Elacridar inhibits the transportation of Vinblastine by ABCB1 (IC50 = 0.043 microM) [6]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Elacridar inhibits the transportation of Quinine by ABCB1 [51]
Affected Drug/Substrate Quinine Modulation Type Inhibition
Cell System LLC-PK1 porcine kidney epithelial (LLC-GA5-COL150) cells-MDR1
DT Modulation Elacridar inhibits the transportation of Mitoxantrone by ABCB1 [52]
Affected Drug/Substrate Mitoxantrone Modulation Type Inhibition
Exogenous Factor Lovastatin Approved Drug
DT Modulation Lovastatin inhibits the transportation of Calcein AM by ABCB1 (IC50 = 10 +/- 4 microM) [53]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System Madin-Darby Canine Kidney (MDCK) cells-MDR1
DT Modulation Lovastatin inhibits the transportation of LDS-751 by ABCB1 (IC50 = 32.7 microM) [4]
Affected Drug/Substrate LDS-751 Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Lovastatin inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 114.4 microM) [4]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Lovastatin inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 26 microM) [54]
Affected Drug/Substrate Daunorubicin Modulation Type Inhibition
DT Modulation Lovastatin inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 67 microM) [54]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
DT Modulation Lovastatin inhibits the transportation of Digoxin by ABCB1 [57]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Troleandomycin Approved Drug
DT Modulation Troleandomycin inhibits the transportation of Calcein AM by ABCB1 (Ki = 483.3 microM) [1]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Troleandomycin inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 68.3 microM) [4]
Affected Drug/Substrate Daunorubicin Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Troleandomycin inhibits the transportation of LDS-751 by ABCB1 (IC50 = 78.2 microM) [4]
Affected Drug/Substrate LDS-751 Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Troleandomycin inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 86.3 microM) [4]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Troleandomycin inhibits the transportation of Vinblastine by ABCB1 (Ki = 87.64 microM) [1]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
Exogenous Factor Vinblastine Approved Drug
DT Modulation Vinblastine inhibits the transportation of Calcein AM by ABCB1 (IC50 = 29 microM) [53]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System Madin-Darby Canine Kidney (MDCK) cells-MDR1
DT Modulation Vinblastine inhibits the transportation of Colchicine by ABCB1 (IC50 = 30.1 microM) [6]
Affected Drug/Substrate Colchicine Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Vinblastine inhibits the transportation of Digoxin by ABCB1 (IC50 = 17.8 microM) [6]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Vinblastine inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 18 microM) [11]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Vinblastine inhibits the transportation of Vinblastine by ABCB1 (IC50 = 89.7 microM) [6]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Vinblastine inhibits the transportation of Rhodamine 123 by ABCB1 [36]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Madin-Darby Canine Kidney (MDCK) cells-MDR1
Exogenous Factor Ketoconazole Approved Drug
DT Modulation Ketoconazole inhibits the transportation of Colchicine by ABCB1 (IC50 = 5.49 microM) [6]
Affected Drug/Substrate Colchicine Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Ketoconazole inhibits the transportation of Digoxin by ABCB1 (IC50 = 3.07 microM) [6]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Ketoconazole inhibits the transportation of Digoxin by ABCB1 (IC50 = 1.34 microM) [49]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Ketoconazole inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 5.6 microM) [11]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Ketoconazole inhibits the transportation of Vinblastine by ABCB1 (IC50 = 6.34 microM) [6]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Ketoconazole inhibits the activity of ABCB1 [58]
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Progesterone Approved Drug
DT Modulation Progesterone inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 96.2 microM) [4]
Affected Drug/Substrate Daunorubicin Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Progesterone inhibits the transportation of LDS-751 by ABCB1 (IC50 = 88.1 microM) [4]
Affected Drug/Substrate LDS-751 Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Progesterone inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 192.2 microM) [4]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Progesterone inhibits the transportation of Calcein AM by ABCB1 [55]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System NIH 3T3 cells-MDR1
DT Modulation Progesterone inhibits the transportation of Cortisol by ABCB1 [56]
Affected Drug/Substrate Cortisol Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Progesterone inhibits the transportation of Vinblastine by ABCB1 [24]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Exogenous Factor Etoposide Approved Drug
DT Modulation Etoposide inhibits the transportation of Calcein AM by ABCB1 (IC50 = 50 microM) [5]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Etoposide inhibits the transportation of Digoxin by ABCB1 (Ki = 768 microM) [7]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Madin-Darby Canine Kidney (MDCK) cells-MDR1
DT Modulation Etoposide inhibits the transportation of Taxol by ABCB1 (Ki = 276 microM) [25]
Affected Drug/Substrate Taxol Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Etoposide inhibits the transportation of Rhodamine 123 by ABCB1 [5]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Etoposide induces the activity of ABCB1 [69]
Exogenous Factor Piperine Natural Product
DT Modulation Piperine inhibits the transportation of Cyclosporine A by ABCB1 (IC50 = 74.1 microM) [59]
Affected Drug/Substrate Cyclosporine A Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Piperine inhibits the transportation of Digoxin by ABCB1 (IC50 = 15.5 microM) [59]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Piperine induces the transportation of Diltiazem by inducing ABCB1 expression [64]
Affected Drug/Substrate Diltiazem Modulation Type Inducer
Cell System Model organism in vivo (rat)
DT Modulation Piperine inhibits the transportation of Fexofenadine by ABCB1 [65]
Affected Drug/Substrate Fexofenadine Modulation Type Inhibition
Cell System Model organism in vivo (rat)
DT Modulation Piperine induces the activity of ABCB1 [68]
Cell System Multiple cell lines of human
Exogenous Factor Reserpine Approved Drug
DT Modulation Reserpine inhibits the transportation of Digoxin by ABCB1 (Ki = 1.38 microM) [7]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Reserpine inhibits the transportation of Rhodamine 123 by ABCB1 [60], [61]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Human breast adenocarcinoma cell line (MCF-7)-MDR1
DT Modulation Reserpine induces the activity of ABCB1 [66]
Cell System Human colon carcinoma cell lines (LS174T)-MDR1
DT Modulation Reserpine inhibits the activity of ABCB1 [70], [71]
Exogenous Factor Grapefruit juice Dietary Constituent
DT Modulation Grapefruit juice inhibits the transportation of Digoxin by ABCB1 [62]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Grapefruit juice peel inhibits the transportation of Digoxin by ABCB1 [62]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Grapefruit juices induces the transportation of Fexofenadine by ABCB1 [62]
Affected Drug/Substrate Fexofenadine Modulation Type Inducer
Cell System Transfected cell lines-MDR1
DT Modulation Grapefruit juices inhibits the transportation of Talinolol by ABCB1 [63]
Affected Drug/Substrate Talinolol Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Grapefruit juice induces the activity of ABCB1 [67]
Cell System Madin darby canine kidney strain cell line (MDCK)-MDR1
Exogenous Factor Miconazole Approved Drug
DT Modulation Miconazole inhibits the transportation of Calcein AM by ABCB1 (Ki = 55.5 microM) [1]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Miconazole inhibits the transportation of Calcein AM by ABCB1 (IC50 = 3.5 microM) [5]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Miconazole inhibits the transportation of Vinblastine by ABCB1 (Ki = 26.36 microM) [1]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Miconazole inhibits the transportation of Rhodamine 123 by ABCB1 [5]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Trifluoperazine Approved Drug
DT Modulation Trifluoperazine inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 7.2 microM) [4]
Affected Drug/Substrate Daunorubicin Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Trifluoperazine inhibits the transportation of LDS-751 by ABCB1 (IC50 = 6.3 microM) [4]
Affected Drug/Substrate LDS-751 Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Trifluoperazine inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 10.9 microM) [4]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Trifluoperazine inhibits the activity of ABCB1 [77]
Exogenous Factor Erythromycin Approved Drug
DT Modulation Erythromycin inhibits the transportation of Digoxin by ABCB1 (IC50 = 10 microM) [1]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Erythromycin inhibits the transportation of Digoxin by ABCB1 (IC50 = 22.7 microM) [72]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Erythromycin inhibits the transportation of Ximelagatran by ABCB1 (IC50 = 119 microM) [74]
Affected Drug/Substrate Ximelagatran Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Erythromycin induces the activity of ABCB1 [75]
Exogenous Factor Ritonavir Approved Drug
DT Modulation Ritonavir inhibits the transportation of Digoxin by ABCB1 (IC50 = 5 microM) [73]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Ritonavir inhibits the transportation of Digoxin by ABCB1 (IC50 = 28.2 microM) [49]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Ritonavir inhibits the transportation of Digoxin by ABCB1 (IC50 = 3.8 microM) [9]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Ritonavir induces the activity of ABCB1 [76]
Exogenous Factor Bromocriptine Approved Drug
DT Modulation Bromocriptine inhibits the transportation of Calcein AM by ABCB1 (Ki = 2.81 microM) [1]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Bromocriptine inhibits the transportation of Vinblastine by ABCB1 (Ki = 3.96 microM) [1]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Bromocriptine inhibits the activity of ABCB1 [86]
Exogenous Factor Amiodarone Approved Drug
DT Modulation Amiodarone inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 22.5 microM) [78]
Affected Drug/Substrate Daunorubicin Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Amiodarone inhibits the transportation of Digoxin by ABCB1 (IC50 = 45.6 microM) [78]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Amiodarone inhibits the transportation of Digoxin by ABCB1 (IC50 = 5.48 microM) [50]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
Exogenous Factor Felodipine Approved Drug
DT Modulation Felodipine inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 26.3 microM) [4]
Affected Drug/Substrate Daunorubicin Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Felodipine inhibits the transportation of LDS-751 by ABCB1 (IC50 = 32.3 microM) [4]
Affected Drug/Substrate LDS-751 Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Felodipine inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 > 60 microM) [4]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
Exogenous Factor Fluphenazine Approved Drug
DT Modulation Fluphenazine inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 6.5 microM) [4]
Affected Drug/Substrate Daunorubicin Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Fluphenazine inhibits the transportation of LDS-751 by ABCB1 (IC50 = 5.7 microM) [4]
Affected Drug/Substrate LDS-751 Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Fluphenazine inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 10.4 microM) [4]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
Exogenous Factor Nifedipine Approved Drug
DT Modulation Nifedipine inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 113 microM) [79]
Affected Drug/Substrate Daunorubicin Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Nifedipine inhibits the transportation of Digoxin by ABCB1 (IC50 = 472 microM) [80]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Nifedipine induces the activity of ABCB1 [66]
Cell System Human colon carcinoma cell lines (LS174T)-MDR1
Exogenous Factor Dipyridamole Approved Drug
DT Modulation Dipyridamole inhibits the transportation of Digoxin by ABCB1 (IC50 = 40 microM) [50]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Dipyridamole inhibits the transportation of Rhodamine 123 by ABCB1 [21]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Mouse T-lymphoma L5178-MDR1
DT Modulation Dipyridamole inhibits the activity of ABCB1 [87]
Exogenous Factor Hypericin Natural Product
DT Modulation Hypericin inhibits the transportation of Ritonavir by ABCB1 (IC50 = 247 microM) [81]
Affected Drug/Substrate Ritonavir Modulation Type Inhibition
Cell System Madin darby canine kidney strain cell line (MDCK)-MDR1
DT Modulation Hypericin induces the activity of ABCB1 [85]
Cell System Human gastrointestinal epithelial cell line (LS-180)-MDR1
Exogenous Factor Quercetin Approved Drug
DT Modulation Quercetin inhibits the transportation of Ritonavir by ABCB1 (IC50 = 26.4 microM) [81]
Affected Drug/Substrate Ritonavir Modulation Type Inhibition
Cell System Madin darby canine kidney strain cell line (MDCK)-MDR1
DT Modulation Quercetin inhibits the transportation of Rhodamine 123 by ABCB1 [82]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Model organism in vivo (rat)
DT Modulation Quercetin induces the transportation of Ritonavir by ABCB1 [81]
Affected Drug/Substrate Ritonavir Modulation Type Inducer
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Garlic extract Natural Product
DT Modulation Garlic extract induces the transportation of Rhodamine 123 by ABCB1 [83]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inducer
Cell System Model organism in vivo (rat)
DT Modulation Garlic extract induces the transportation of Saquinavir by ABCB1 [84]
Affected Drug/Substrate Saquinavir Modulation Type Inducer
Cell System Healthy people
Exogenous Factor Dihydroergocristine Approved Drug
DT Modulation Dihydroergocristine inhibits the transportation of Calcein AM by ABCB1 (Ki = 511 microM) [1]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Dihydroergocristine inhibits the transportation of Vinblastine by ABCB1 (Ki = 16 microM) [1]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
Exogenous Factor Dihydroergotamine Approved Drug
DT Modulation Dihydroergotamine inhibits the transportation of Calcein AM by ABCB1 (Ki > 1000 microM) [1]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Dihydroergotamine inhibits the transportation of Vinblastine by ABCB1 (Ki = 119.94 microM) [1]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
Exogenous Factor Ergonovine Approved Drug
DT Modulation Ergonovine inhibits the transportation of Calcein AM by ABCB1 (Ki = 115.5 microM) [1]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Ergonovine inhibits the transportation of Vinblastine by ABCB1 (Ki > 100 microM) [1]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
Exogenous Factor Ergotamine Approved Drug
DT Modulation Ergotamine inhibits the transportation of Calcein AM by ABCB1 (Ki = 98.9 microM) [1]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Ergotamine inhibits the transportation of Vinblastine by ABCB1 (Ki = 14.25 microM) [1]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
Exogenous Factor Fluconazole Approved Drug
DT Modulation Fluconazole inhibits the transportation of Calcein AM by ABCB1 (Ki > 1000 microM) [1]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Fluconazole inhibits the transportation of Vinblastine by ABCB1 (Ki > 400 microM) [1]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
Exogenous Factor Hydrocortisone Approved Drug
DT Modulation Hydrocortisone inhibits the transportation of Calcein AM by ABCB1 (IC50 = 50 microM) [5]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Hydrocortisone inhibits the transportation of Rhodamine 123 by ABCB1 [5]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Morphine Approved Drug
DT Modulation Morphine inhibits the transportation of Calcein AM by ABCB1 (IC50 = 50 microM) [5]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Morphine inhibits the transportation of Rhodamine 123 by ABCB1 [5]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Pimozide Approved Drug
DT Modulation Pimozide inhibits the transportation of Calcein AM by ABCB1 (IC50 = 2.9 microM) [5]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Pimozide inhibits the transportation of Rhodamine 123 by ABCB1 [5]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Amlodipine Approved Drug
DT Modulation Amlodipine inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 22 microM) [88]
Affected Drug/Substrate Daunorubicin Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Amlodipine inhibits the transportation of Rhodamine 123 by ABCB1 [21]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Mouse T-lymphoma L5178-MDR1
Exogenous Factor Azelastine Approved Drug
DT Modulation Azelastine inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 16 microM) [78]
Affected Drug/Substrate Daunorubicin Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Azelastine inhibits the transportation of Digoxin by ABCB1 (IC50 = 30 microM) [78]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
Exogenous Factor Astemizole Drug Withdrawn
DT Modulation Astemizole inhibits the transportation of Digoxin by ABCB1 (IC50 = 2.73 microM) [49]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Astemizole inhibits the transportation of Rhodamine 123 by ABCB1 [21]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Mouse T-lymphoma L5178-MDR1
Exogenous Factor Itraconazole Approved Drug
DT Modulation Itraconazole inhibits the transportation of Digoxin by ABCB1 (IC50 = 2 microM) [73]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Itraconazole inhibits the transportation of Digoxin by ABCB1 (IC50 = 0.95 microM) [49]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
Exogenous Factor Nitrendipine Approved Drug
DT Modulation Nitrendipine inhibits the transportation of Digoxin by ABCB1 (IC50 = 68.2 microM) [80]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
DT Modulation Nitrendipine inhibits the transportation of Calcein AM by ABCB1 [94]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
Exogenous Factor St Johns wort extract Natural Product
DT Modulation St Johns wort extract inhibits the transportation of Digoxin by ABCB1 (IC50 = 15.4 microM) [89]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation St Johns wort extract induces the transportation of Digoxin by increasing the expression of ABCB1 [99]
Affected Drug/Substrate Digoxin Modulation Type Inducer
Cell System Model organism in vivo (rat)
Exogenous Factor Nefazodone Approved Drug
DT Modulation Nefazodone inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 4.7 microM) [90]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Paclitaxel Approved Drug
DT Modulation Paclitaxel inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 54 microM) [11]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
Exogenous Factor Tamoxifen Approved Drug
DT Modulation Tamoxifen inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 7.1 microM) [11]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
DT Modulation Tamoxifen induces the activity of ABCB1 [115]
Exogenous Factor Naringenin Drug in Phase 1 Trial
DT Modulation Naringenin inhibits the transportation of Talinolol by ABCB1 (IC50 = 2409 microM) [63]
Affected Drug/Substrate Talinolol Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Naringenin inhibits the transportation of Rhodamine 123 by ABCB1 [82]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Model organism in vivo (rat)
Exogenous Factor Rifampicin Approved Drug
DT Modulation Rifampicin inhibits the transportation of Azidopine by ABCB1 [91]
Affected Drug/Substrate Azidopine Modulation Type Inhibition
Cell System Myelogenous leukemia cell line (K562)-MDR1
DT Modulation Rifampicin induces the activity of ABCB1 [66]
Cell System Human colon carcinoma cell lines (LS174T)-MDR1
Exogenous Factor Amprenavir Approved Drug
DT Modulation Amprenavir inhibits the transportation of Calcein AM by ABCB1 [92]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Amprenavir induces the activity of ABCB1 [104]
Exogenous Factor Haloperidol Approved Drug
DT Modulation Haloperidol inhibits the transportation of Calcein AM by ABCB1 [93]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Haloperidol inhibits the transportation of Calcein AM by ABCB1 [55]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System NIH 3T3 cells-MDR1
Exogenous Factor Indinavir Approved Drug
DT Modulation Indinavir inhibits the transportation of Calcein AM by ABCB1 [92]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
Exogenous Factor Pyronaridine Approved Drug
DT Modulation Pyronaridine inhibits the transportation of doxorubicin by ABCB1 [95]
Affected Drug/Substrate doxorubicin Modulation Type Inhibition
Cell System Human breast adenocarcinoma cell line (MCF-7)/ADR
DT Modulation Pyronaridine inhibits the transportation of Rhodamine 123 by ABCB1 [95]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Exogenous Factor Carbamazepine Approved Drug
DT Modulation Carbamazepine induces the transportation of Fexofenadine by ABCB1 [96]
Affected Drug/Substrate Fexofenadine Modulation Type Inducer
Cell System Twelve healthy Japanese volunteers
DT Modulation Carbamazepine induces the activity of ABCB1 [109]
Exogenous Factor Tariquidar Discontinued Drug
DT Modulation Tariquidar inhibits the transportation of Rhodamine 123 by ABCB1 [97]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
DT Modulation Tariquidar inhibits the activity of ABCB1 [117]
Exogenous Factor Gingerol Natural Product
DT Modulation Gingerol inhibits the transportation of Daunorubicin by ABCB1 [98]
Affected Drug/Substrate Daunorubicin Modulation Type Inhibition
Cell System Multiple drug-resistant human KB carcinoma cell line (KB-C2)-MDR1
DT Modulation Gingerol inhibits the transportation of Rhodamine 123 by ABCB1 [98]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Multiple drug-resistant human KB carcinoma cell line (KB-C2)-MDR1
Exogenous Factor Hyperforin Investigative Drug
DT Modulation Hyperforin inhibits the transportation of Ritonavir by ABCB1 [81]
Affected Drug/Substrate Ritonavir Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
DT Modulation Hyperforin induces the activity of ABCB1 [85]
Cell System Human gastrointestinal epithelial cell line (LS-180)-MDR1
Exogenous Factor Genistein Natural Product
DT Modulation Genistein induces the transportation of Sorafenib by increasing ABCB1 expression at translational and transcriptional levels [100]
Affected Drug/Substrate Sorafenib Modulation Type Inducer
Cell System Human hepatocellular carcinoma cell line (HepG2)-MDR1
DT Modulation Genistein induces the activity of ABCB1 [100]
Cell System Human hepatocellular carcinoma cell line (HepG2)-MDR1
Exogenous Factor Apatinib Approved Drug
DT Modulation Apatinib inhibits the transportation of Adriamycin by ABCB1 [38]
Affected Drug/Substrate Adriamycin Modulation Type Inhibition
DT Modulation Apatinib inhibits the transportation of Rhodamine 123 by ABCB1 [38]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Exogenous Factor Telaprevir Approved Drug
DT Modulation Telaprevir inhibits the transportation of Calcein by ABCB1 [101]
Affected Drug/Substrate Calcein Modulation Type Inhibition
DT Modulation Telaprevir inhibits the activity of ABCB1 [116]
Exogenous Factor Venlafaxine Approved Drug
DT Modulation Venlafaxine inhibits the transportation of Calcein by ABCB1 [102]
Affected Drug/Substrate Calcein Modulation Type Inhibition
Exogenous Factor Cobicistat Approved Drug
DT Modulation Cobicistat inhibits the transportation of Dabigatran by ABCB1 [103]
Affected Drug/Substrate Dabigatran Modulation Type Inhibition
DT Modulation Cobicistat inhibits the activity of ABCB1 [110]
Exogenous Factor Arsenic trioxide Approved Drug
DT Modulation Arsenic trioxide inhibits the activity of ABCB1 [105]
Exogenous Factor Atorvastatin Approved Drug
DT Modulation Atorvastatin inhibits the activity of ABCB1 [106]
DT Modulation Atorvastatin modulates the activity of ABCB1 [106]
Exogenous Factor Biricodar Approved Drug
DT Modulation Biricodar inhibits the activity of ABCB1 [107]
DT Modulation Biricodar modulates the activity of ABCB1 [108]
Exogenous Factor Cytarabine Approved Drug
DT Modulation Cytarabine induces the activity of ABCB1 [111]
Exogenous Factor Doxorubicin Approved Drug
DT Modulation Doxorubicin induces the activity of ABCB1 [112], [113]
DT Modulation Doxorubicin inhibits the activity of ABCB1 [112], [113]
Exogenous Factor Indomethacin Approved Drug
DT Modulation Indomethacin inhibits the activity of ABCB1 [114]
Exogenous Factor Nelfinavir Approved Drug
DT Modulation Nelfinavir induces the activity of ABCB1 [104]
Exogenous Factor Simvastatin Approved Drug
DT Modulation Simvastatin inhibits the transportation of Calcein AM by ABCB1 (IC50 = 10 +/- 8 microM) [53]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System Madin-Darby Canine Kidney (MDCK) cells-MDR1
Exogenous Factor Desloratadine Approved Drug
DT Modulation Desloratadine inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 43 microM) [118]
Affected Drug/Substrate Daunorubicin Modulation Type Inhibition
Cell System NIH-3T3-G185-MDR1
Exogenous Factor Nisoldipine Approved Drug
DT Modulation Nisoldipine inhibits the transportation of Digoxin by ABCB1 (IC50 = 44.1 microM) [80]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
Exogenous Factor Telithromycin Approved Drug
DT Modulation Telithromycin inhibits the transportation of Digoxin by ABCB1 (IC50 = 1.8 microM) [72]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Clarithromycin Approved Drug
DT Modulation Clarithromycin inhibits the transportation of Digoxin by ABCB1 (IC50 = 4.1 microM) [72]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Sufentanil Approved Drug
DT Modulation Sufentanil inhibits the transportation of Digoxin by ABCB1 (IC50 = 4.5 microM) [119]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Fentanyl Approved Drug
DT Modulation Fentanyl inhibits the transportation of Digoxin by ABCB1 (IC50 = 6.5 microM) [119]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Roxithromycin Drug Withdrawn
DT Modulation Roxithromycin inhibits the transportation of Digoxin by ABCB1 (IC50 = 15.4 microM) [72]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Omeprazole Approved Drug
DT Modulation Omeprazole inhibits the transportation of Digoxin by ABCB1 (IC50 = 17.7 microM) [120]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Pantoprazole Approved Drug
DT Modulation Pantoprazole inhibits the transportation of Digoxin by ABCB1 (IC50 = 17.9 microM) [120]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Azithromycin Approved Drug
DT Modulation Azithromycin inhibits the transportation of Digoxin by ABCB1 (IC50 = 21.8 microM) [72]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Ginkgo biloba extract Natural Product
DT Modulation Ginkgo biloba extract inhibits the transportation of Digoxin by ABCB1 (IC50 = 23.6 microM) [89]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Alfentanil Approved Drug
DT Modulation Alfentanil inhibits the transportation of Digoxin by ABCB1 (IC50 = 112 microM) [119]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Atovaquone Approved Drug
DT Modulation Atovaquone inhibits the transportation of N-methyl quinidine by ABCB1 (IC50 = 6.8 microM) [121]
Affected Drug/Substrate N-methyl quinidine Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MDR1
Exogenous Factor Acetochlor Natural Product
DT Modulation Acetochlor inhibits the transportation of Paclitaxel by ABCB1 (IC50 = 25 microM) [122]
Affected Drug/Substrate Paclitaxel Modulation Type Inhibition
Cell System Myelogenous leukemia cell line (K562)-MDR1
Exogenous Factor Alachlor Natural Product
DT Modulation Alachlor inhibits the transportation of Paclitaxel by ABCB1 (IC50 = 25 microM) [122]
Affected Drug/Substrate Paclitaxel Modulation Type Inhibition
Cell System Myelogenous leukemia cell line (K562)-MDR1
Exogenous Factor Cigarette smoke condensate Natural Product
DT Modulation Cigarette smoke condensate inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 224.3 microM) [123]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Human hepatoma HepaRG cells-MDR1
Exogenous Factor Chlordecone Natural Product
DT Modulation Chlordecone inhibits the transportation of Rhodamine 123 by ABCB1 (IC50 = 138.8 microM) [124]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Human breast adenocarcinoma cell line (MCF-7)-MDR1
Exogenous Factor Allicin Natural Product
DT Modulation Allicin inhibits the transportation of Ritonavir by ABCB1 (IC50 = 119.1 microM) [81]
Affected Drug/Substrate Ritonavir Modulation Type Inhibition
Cell System Madin darby canine kidney strain cell line (MDCK)-MDR1
Exogenous Factor Kaempferol Investigative Drug
DT Modulation Kaempferol inhibits the transportation of Ritonavir by ABCB1 (IC50 = 146.7 microM) [81]
Affected Drug/Substrate Ritonavir Modulation Type Inhibition
Cell System Madin darby canine kidney strain cell line (MDCK)-MDR1
Exogenous Factor 6,7-epoxybergamottin Natural Product
DT Modulation 6,7-epoxybergamottin inhibits the transportation of Talinolol by ABCB1 (IC50 = 0.7 microM) [63]
Affected Drug/Substrate Talinolol Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor 6,7-dihydroxybergamottin Natural Product
DT Modulation 6,7-dihydroxybergamottin inhibits the transportation of Talinolol by ABCB1 (IC50 = 34 microM) [63]
Affected Drug/Substrate Talinolol Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Naringin Investigative Drug
DT Modulation Naringin inhibits the transportation of Talinolol by ABCB1 (IC50 = 236 microM) [63]
Affected Drug/Substrate Talinolol Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor p,p'-dichlorodiphenyltrichloroethane (DDT) Environmental toxicant
DT Modulation p,p'-DDT inhibits the transportation of Verapamil by ABCB1 (IC50 = 3.8 microM) [125]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Cell System Spodoptera frugiperda (Sf9) cells-MDR1
Exogenous Factor o,p'-dichlorodiphenyltrichloroethane (DDT) Environmental toxicant
DT Modulation O,p'-DDT inhibits the transportation of Verapamil by ABCB1 (IC50 = 7.8 microM) [125]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Cell System Spodoptera frugiperda (Sf9) cells-MDR1
Exogenous Factor p,p'-tetrachlorodiphenylethane (DDD) Environmental toxicant
DT Modulation p,p'-DDD inhibits the transportation of Verapamil by ABCB1 (IC50 = 10.7 microM) [125]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Cell System Spodoptera frugiperda (Sf9) cells-MDR1
Exogenous Factor Endosulfan Natural Product
DT Modulation Endosulfan inhibits the transportation of Verapamil by ABCB1 (IC50 = 1.5 microM) [126]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Cell System NIH 3T3 cells-MDR1
Exogenous Factor Phosalone Natural Product
DT Modulation Phosalone inhibits the transportation of Verapamil by ABCB1 (IC50 = 1.5 microM) [126]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Cell System NIH 3T3 cells-MDR1
Exogenous Factor Propiconazole Natural Product
DT Modulation Propiconazole inhibits the transportation of Verapamil by ABCB1 (IC50 = 1.5 microM) [126]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Cell System NIH 3T3 cells-MDR1
Exogenous Factor Diazinon Natural Product
DT Modulation Diazinon inhibits the transportation of Verapamil by ABCB1 (IC50 = 58.4 microM) [127]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Cell System NIH 3T3 cells-MDR1
Exogenous Factor Metoprolol Approved Drug
DT Modulation Metoprolol inhibits the transportation of Verapamil by ABCB1 (Ki = 200 microM) [128]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Pyrethroids Natural Product
DT Modulation Pyrethroids inhibits the transportation of Verapamil by ABCB1 (IC50 = 65.5 microM) [129]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MDR1
Exogenous Factor Tetramethrin Natural Product
DT Modulation Tetramethrin inhibits the transportation of Verapamil by ABCB1 (IC50 = 100 microM) [129]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MDR1
Exogenous Factor Erlotinib Approved Drug
DT Modulation Erlotinib inhibits the transportation of Vincristine by ABCB1 (IC50 = 2 microM) [31]
Affected Drug/Substrate Vincristine Modulation Type Inhibition
Cell System Myelogenous leukemia cell line (K562)-MDR1
Exogenous Factor Paroxetine Approved Drug
DT Modulation Paroxetine inhibits the transportation of Calcein by ABCB1 (IC50 = 29.8 microM) [102]
Affected Drug/Substrate Calcein Modulation Type Inhibition
Exogenous Factor Sertraline Approved Drug
DT Modulation Sertraline inhibits the transportation of Calcein by ABCB1 (IC50 = 31.8 microM) [102]
Affected Drug/Substrate Calcein Modulation Type Inhibition
Exogenous Factor Loratadine Approved Drug
DT Modulation Loratadine inhibits the transportation of Daunorubicin by ABCB1 (IC50 = 11.4 microM) [118]
Affected Drug/Substrate Daunorubicin Modulation Type Inhibition
Exogenous Factor Lomerizine Approved Drug
DT Modulation Lomerizine inhibits the transportation of Calcein by ABCB1 [130]
Affected Drug/Substrate Calcein Modulation Type Inhibition
Cell System Myelogenous leukemia cell line (K562)-MDR1
Exogenous Factor Benzocaine Approved Drug
DT Modulation Benzocaine inhibits the transportation of Calcein AM by ABCB1 [55]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System NIH 3T3 cells-MDR1
Exogenous Factor Prednisone Approved Drug
DT Modulation Prednisone inhibits the transportation of Calcein AM by ABCB1 [55]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System NIH 3T3 cells-MDR1
Exogenous Factor Tetracaine Approved Drug
DT Modulation Tetracaine inhibits the transportation of Calcein AM by ABCB1 [55]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System NIH 3T3 cells-MDR1
Exogenous Factor Trimipramine Approved Drug
DT Modulation Trimipramine inhibits the transportation of Calcein AM by ABCB1 [55]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System NIH 3T3 cells-MDR1
Exogenous Factor Chlorprothixene Approved Drug
DT Modulation Chlorprothixene inhibits the transportation of Calcein AM by ABCB1 [93]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
Exogenous Factor Clomipramine Approved Drug
DT Modulation Clomipramine inhibits the transportation of Calcein AM by ABCB1 [93]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
Exogenous Factor Lopinavir Approved Drug
DT Modulation Lopinavir inhibits the transportation of Calcein AM by ABCB1 [92]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
Exogenous Factor Maprotiline Approved Drug
DT Modulation Maprotiline inhibits the transportation of Calcein AM by ABCB1 [93]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
Exogenous Factor Mebendazole Approved Drug
DT Modulation Mebendazole inhibits the transportation of Calcein AM by ABCB1 [94]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
Exogenous Factor Glibenclamide Approved Drug
DT Modulation Glibenclamide inhibits the transportation of Colchicine by ABCB1 [15]
Affected Drug/Substrate Colchicine Modulation Type Inhibition
Cell System Human T-cell line (CEM)/Tumour cell line-MDR1
Exogenous Factor Dolutegravir Approved Drug
DT Modulation Dolutegravir inhibits the transportation of Digoxin by ABCB1 [131]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
Exogenous Factor Doxazosin Approved Drug
DT Modulation Doxazosin inhibits the transportation of Digoxin by ABCB1 [132]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MDR1
Exogenous Factor Caffeine Approved Drug
DT Modulation Caffeine inhibits the transportation of Digoxin by ABCB1 [57]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Chlorzoxazone Approved Drug
DT Modulation Chlorzoxazone inhibits the transportation of Digoxin by ABCB1 [57]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Capsaicin Approved Drug
DT Modulation Capsaicin inhibits the transportation of Fexofenadine by ABCB1 [133]
Affected Drug/Substrate Fexofenadine Modulation Type Inhibition
Cell System Model organism in vivo (rat)
Exogenous Factor Bepridil Approved Drug
DT Modulation Bepridil inhibits the transportation of Rhodamine 123 by ABCB1 [134]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System NIH 3T3 cells-MDR1
Exogenous Factor Chlorpropamide Approved Drug
DT Modulation Chlorpropamide inhibits the transportation of Rhodamine 123 by ABCB1 [134]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System NIH 3T3 cells-MDR1
Exogenous Factor Prochlorperazine Approved Drug
DT Modulation Prochlorperazine inhibits the transportation of Rhodamine 123 by ABCB1 [134]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System NIH 3T3 cells-MDR1
Exogenous Factor Promethazine Approved Drug
DT Modulation Promethazine inhibits the transportation of Rhodamine 123 by ABCB1 [134]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System NIH 3T3 cells-MDR1
Exogenous Factor Aprindine Approved Drug
DT Modulation Aprindine inhibits the transportation of Rhodamine 123 by ABCB1 [21]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Mouse T-lymphoma L5178-MDR1
Exogenous Factor Aripiprazole Approved Drug
DT Modulation Aripiprazole inhibits the transportation of Rhodamine 123 by ABCB1 [21]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Mouse T-lymphoma L5178-MDR1
Exogenous Factor Loperamide Approved Drug
DT Modulation Loperamide inhibits the transportation of Rhodamine 123 by ABCB1 [21]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Mouse T-lymphoma L5178-MDR1
Exogenous Factor Repaglinide Approved Drug
DT Modulation Repaglinide inhibits the transportation of Rhodamine 123 by ABCB1 [21]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Mouse T-lymphoma L5178-MDR1
Exogenous Factor Ziprasidone Approved Drug
DT Modulation Ziprasidone inhibits the transportation of Rhodamine 123 by ABCB1 [21]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Mouse T-lymphoma L5178-MDR1
Exogenous Factor Protriptyline Approved Drug
DT Modulation Protriptyline inhibits the transportation of Rhodamine 123 by ABCB1 [134]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Brecanavir Discontinued Drug
DT Modulation Brecanavir inhibits the transportation of Calcein AM by ABCB1 [92]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
Exogenous Factor Miltirone Discontinued Drug
DT Modulation Miltirone inhibits the transportation of Doxorubicin by ABCB1 [135]
Affected Drug/Substrate Doxorubicin Modulation Type Inhibition
Cell System Human hepatoma HepaRG cells-MDR1
Exogenous Factor Curcumin Drug in Phase 3 Trial
DT Modulation Curcumin inhibits the transportation of Rhodamine 123 by ABCB1 [136]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Multidrug resistance human gastric carcinoma cell line (SGC7901/VCR)-MDR1
Exogenous Factor Alprenolol Drug Withdrawn
DT Modulation Alprenolol inhibits the transportation of Rhodamine 123 by ABCB1 [21]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Mouse T-lymphoma L5178-MDR1
Exogenous Factor Sertindole Drug Withdrawn
DT Modulation Sertindole inhibits the transportation of Rhodamine 123 by ABCB1 [21]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Mouse T-lymphoma L5178-MDR1
Exogenous Factor Silibinin Drug in Phase 2/3 Trial
DT Modulation Silibinin inhibits the transportation of Ritonavir by ABCB1 [81]
Affected Drug/Substrate Ritonavir Modulation Type Inhibition
Cell System Madin darby canine kidney strain cell line (MDCK)-MDR1
Exogenous Factor p,p'-dichlorodiphenyldichloroethane (DDE) Environmental toxicant
DT Modulation p,p'-DDE inhibits the transportation of Verapamil by ABCB1 [125]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Cell System Spodoptera frugiperda (Sf9) cells-MDR1
Exogenous Factor Hypericum perforatum Natural Product
DT Modulation Hypericum perforatum induces the transportation of Amitriptyline by ABCB1 [137]
Affected Drug/Substrate Amitriptyline Modulation Type Inducer
Cell System Depression patients
Exogenous Factor 2'-Hydroxychalcone Investigative Drug
DT Modulation 2'-Hydroxychalcone inhibits the transportation of Calcein AM by ABCB1 [138]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System Doxorubicin resistant A2780adr cell lines-MDR1
Exogenous Factor Glabridin Natural Product
DT Modulation Glabridin inhibits the transportation of Daunorubicin by ABCB1 [139]
Affected Drug/Substrate Daunorubicin Modulation Type Inhibition
Cell System Multiple drug-resistant human KB carcinoma cell line (KB-C2)-MDR1
Exogenous Factor Glycyrrhetinic acid Natural Product
DT Modulation Glycyrrhetinic acid inhibits the transportation of Daunorubicin by ABCB1 [139]
Affected Drug/Substrate Daunorubicin Modulation Type Inhibition
Cell System Multiple drug-resistant human KB carcinoma cell line (KB-C2)-MDR1
Exogenous Factor Fructose Natural Product
DT Modulation Fructose inhibits the transportation of Digoxin by decreasing the expression and activity of the ABCB1 [140]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Model organism in vivo (Male Sprague-Dawley rats)
Exogenous Factor Echinacea extract Natural Product
DT Modulation Echinacea extract inhibits the transportation of Digoxin by ABCB1 [141]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Echinacea purpurea Natural Product
DT Modulation Echinacea purpurea inhibits the transportation of Digoxin by ABCB1 [141]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor (-)Epicatechin Natural Product
DT Modulation (-)Epicatechin induces the transportation of LDS-751 by ABCB1 [142]
Affected Drug/Substrate LDS-751 Modulation Type Inducer
Cell System NIH-3T3-G185-MDR1
Exogenous Factor Chloroacetanilides Natural Product
DT Modulation Chloroacetanilides inhibits the transportation of Paclitaxel by ABCB1 [122]
Affected Drug/Substrate Paclitaxel Modulation Type Inhibition
Cell System Myelogenous leukemia cell line (K562)-MDR1
Exogenous Factor PEG 300 Pharmaceutical excipient
DT Modulation PEG 300 inhibits the transportation of Ranitidine by ABCB1 [143]
Affected Drug/Substrate Ranitidine Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor PEG 400 Pharmaceutical excipient
DT Modulation PEG 400 inhibits the transportation of Ranitidine by ABCB1 [143]
Affected Drug/Substrate Ranitidine Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Ginsenoside Rg3 Natural Product
DT Modulation Ginsenoside Rg3 inhibits the transportation of Rhodamine 123 by ABCB1 in a competitive manner [144]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Multidrug-resistant human fibroblast carcinoma cell line (KBV20C)-MDR1
Exogenous Factor Daidzein Investigative Drug
DT Modulation Daidzein induces the transportation of Rhodamine 123 by ABCB1 [145]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inducer
Cell System Human colon carcinoma LS-180 cells (LS-180V)-MDR1
Exogenous Factor Sesamin Natural Product
DT Modulation Sesamin inhibits the transportation of Rhodamine 123 by significantly increasing the mRNA expression of ABCB1 [145]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Human colon carcinoma LS-180 cells (LS-180V)-MDR1
Exogenous Factor Schisandra chinensis extract Natural Product
DT Modulation Schisandra chinensis extract inhibits the transportation of Talinolol by ABCB1 [146]
Affected Drug/Substrate Talinolol Modulation Type Inhibition
Cell System Healthy people
Exogenous Factor Xanthohumol Natural Product
DT Modulation Xanthohumol inhibits the transportation of Tetraethylammonium by ABCB1 [147]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2); LLC-PK1 vesicles
Exogenous Factor Fangchinoline Natural Product
DT Modulation Fangchinoline inhibits the transportation of Verapamil by ABCB1 [148]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Cell System Human colon adenocarcinoma cell line (HCT15)-MDR1
Exogenous Factor Tetrandine Natural Product
DT Modulation Tetrandine inhibits the transportation of Verapamil by ABCB1 [148]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Cell System Human colon adenocarcinoma cell line (HCT15)-MDR1
Exogenous Factor Reboxetine Approved Drug
DT Modulation Reboxetine inhibits the transportation of Calcein by ABCB1 [102]
Affected Drug/Substrate Calcein Modulation Type Inhibition
Exogenous Factor Fluvoxamine Approved Drug
DT Modulation Fluvoxamine inhibits the transportation of Calcein AM by ABCB1 [102]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Exogenous Factor Sesquiterpene Approved Drug
DT Modulation Sesquiterpene inhibits the transportation of Colchicine by ABCB1 [149]
Affected Drug/Substrate Colchicine Modulation Type Inhibition
Exogenous Factor Simeprevir Approved Drug
DT Modulation Simeprevir inhibits the transportation of Digoxin by ABCB1 [150]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Exogenous Factor Carvedilol Approved Drug
DT Modulation Carvedilol inhibits the transportation of Doxorubicin by ABCB1 [151]
Affected Drug/Substrate Doxorubicin Modulation Type Inhibition
Exogenous Factor Dronedarone Approved Drug
DT Modulation Dronedarone inhibits the transportation of Edoxaban by ABCB1 [152]
Affected Drug/Substrate Edoxaban Modulation Type Inhibition
Exogenous Factor Crizotinib Approved Drug
DT Modulation Crizotinib inhibits the transportation of Rhodamine 123 by ABCB1 [153]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Exogenous Factor Vandetanib Approved Drug
DT Modulation Vandetanib inhibits the transportation of Rhodamine 123 by ABCB1 [154]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Exogenous Factor Caspofungin Approved Drug
DT Modulation Caspofungin inhibits the transportation of Vinblastine by ABCB1 [155]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Exogenous Factor Estramustine Approved Drug
DT Modulation Estramustine inhibits the transportation of Vinblastine by ABCB1 [156]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Exogenous Factor Istradefylline Drug in Phase 3 Trial
DT Modulation Istradefylline inhibits the transportation of Atorvastatin by ABCB1 [157]
Affected Drug/Substrate Atorvastatin Modulation Type Inhibition
Exogenous Factor Epothilone D Discontinued Drug
DT Modulation Epothilone D inhibits the transportation of Calcein AM by ABCB1 [158]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Exogenous Factor Ezogabine Drug Withdrawn
DT Modulation Ezogabine inhibits the transportation of Digoxin by ABCB1 [159]
Affected Drug/Substrate Digoxin Modulation Type Inhibition
Exogenous Factor Ginseng extract Natural Product
DT Modulation Ginseng extracts inhibits the transportation of Verapamil by ABCB1 [160]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Exogenous Factor Buspirone Approved Drug
DT Modulation Buspirone inhibits the activity of ABCB1 [93]
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MDR1
Exogenous Factor Digoxin Approved Drug
DT Modulation Digoxin induces the activity of ABCB1 [161], [162]
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Liothyronine Approved Drug
DT Modulation Liothyronine induces the activity of ABCB1 [163]
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Calcitriol Approved Drug
DT Modulation Calcitriol inhibits the activity of ABCB1 [164]
Cell System Human embryonic kidney 293 cells (HEK293)-MDR1
Exogenous Factor Clotrimazole Approved Drug
DT Modulation Clotrimazole induces the activity of ABCB1 [66]
Cell System Human colon carcinoma cell lines (LS174T)-MDR1
Exogenous Factor Dexamethasone Approved Drug
DT Modulation Dexamethasone induces the activity of ABCB1 [66]
Cell System Human colon carcinoma cell lines (LS174T)-MDR1
Exogenous Factor Bexarotene Approved Drug
DT Modulation Bexarotene induces the activity of ABCB1 [165]
Cell System Human BBB model derived from hematopoietic stem cells
Exogenous Factor Tetrahydrocurcumin Natural Product
DT Modulation Tetrahydrocurcumin inhibits the activity of ABCB1 [166]
Cell System Multidrug-resistant subclone KB-V-1 cells
Exogenous Factor Acteoside Natural Product
DT Modulation Acteoside inhibits the activity of ABCB1 [167]
Cell System Model organism in vivo (rat)
Exogenous Factor Agnuside Natural Product
DT Modulation Agnuside inhibits the activity of ABCB1 [167]
Cell System Model organism in vivo (rat)
Exogenous Factor Catechin Natural Product
DT Modulation Catechin inhibits the activity of ABCB1 [167]
Cell System Model organism in vivo (rat)
Exogenous Factor Chlorogenic acid Investigative Drug
DT Modulation Chlorogenic acid inhibits the activity of ABCB1 [167]
Cell System Model organism in vivo (rat)
Exogenous Factor Glycyrrhizin (high concentration) Drug in Phase 3 Trial
DT Modulation Glycyrrhizin (high concentration) inhibits the activity of ABCB1 [167]
Cell System Model organism in vivo (rat)
Exogenous Factor Negundoside Natural Product
DT Modulation Negundoside induces the activity of ABCB1 [167]
Cell System Model organism in vivo (rat)
Exogenous Factor Nobiletin Natural Product
DT Modulation Nobiletin inhibits the activity of ABCB1 [168]
Cell System Model organism in vivo (rat)
Exogenous Factor Oleanolic acid Natural Product
DT Modulation Oleanolic acid induces the activity of ABCB1 [167]
Cell System Model organism in vivo (rat)
Exogenous Factor Picroside-I Natural Product
DT Modulation Picroside-I induces the activity of ABCB1 [167]
Cell System Model organism in vivo (rat)
Exogenous Factor Picroside-II Natural Product
DT Modulation Picroside-II inhibits the activity of ABCB1 [167]
Cell System Model organism in vivo (rat)
Exogenous Factor Piperine (high concentration) Natural Product
DT Modulation Piperine (high concentration) inhibits the activity of ABCB1 [167]
Cell System Model organism in vivo (rat)
Exogenous Factor Rutin Natural Product
DT Modulation Rutin inhibits the activity of ABCB1 [168]
Cell System Model organism in vivo (rat)
Exogenous Factor Santonin Natural Product
DT Modulation Santonin inhibits the activity of ABCB1 [167]
Cell System Model organism in vivo (rat)
Exogenous Factor Tangeretin Natural Product
DT Modulation Tangeretin inhibits the activity of ABCB1 [168]
Cell System Model organism in vivo (rat)
Exogenous Factor Echinacea pallida roots extract Natural Product
DT Modulation Echinacea pallida roots extract inhibits the activity of ABCB1 [169]
Cell System Human proximal tubule HK-2 cell line (HK-2)-MDR1
Exogenous Factor Icaritin Drug in Phase 2 Trial
DT Modulation Icaritin inhibits the activity of ABCB1 [58]
Cell System Human enterocyte-like 2 cell (Caco-2)-MDR1
Exogenous Factor Corticosterone Investigative Drug
DT Modulation Corticosterone induces the activity of ABCB1 [66]
Cell System Human colon carcinoma cell lines (LS174T)-MDR1
Exogenous Factor Cyanidin-3-rutinoside Natural Product
DT Modulation Cyanidin-3-rutinoside inhibits the activity of ABCB1 [170]
Cell System Human breast adenocarcinoma cell line (MCF-7)-BSEP
Exogenous Factor Delphinidin-3-Glucoside Natural Product
DT Modulation Delphinidin-3-Glucoside inhibits the activity of ABCB1 [170]
Cell System Human breast adenocarcinoma cell line (MCF-7)-BSEP
Exogenous Factor Malvidin-3-galactoside Natural Product
DT Modulation Malvidin-3-galactoside inhibits the activity of ABCB1 [170]
Cell System Human breast adenocarcinoma cell line (MCF-7)-BSEP
Exogenous Factor Malvidin-3-glucoside Natural Product
DT Modulation Malvidin-3-glucoside inhibits the activity of ABCB1 [170]
Cell System Human breast adenocarcinoma cell line (MCF-7)-BSEP
Exogenous Factor Pelargonidin-3,5-diglucoside Natural Product
DT Modulation Pelargonidin-3,5-diglucoside inhibits the activity of ABCB1 [170]
Cell System Human breast adenocarcinoma cell line (MCF-7)-BSEP
Exogenous Factor Protopanaxatriol ginsenoside Natural Product
DT Modulation Protopanaxatriol ginsenoside inhibits the activity of ABCB1 [171]
Cell System Doxorubicin-resistant Acute myelogenous leukemia cell line (AML-2/D100)-MDR1
Exogenous Factor Decitabine Approved Drug
DT Modulation Decitabine restores drug sensitivity by depressing ABCB1 activity through MAPK signaling pathway [172]
Cell System K562/ADR cells and MCF-7/ADR cells
Exogenous Factor Dihydromyricetin Approved Drug
DT Modulation Dihydromyricetin inhibits the transporation of adriamycin by ABCB1 through ERK/Akt signaling pathways (IC50 = 0.172 microM) [173]
Affected Drug/Substrate Adriamycin Modulation Type Inhibition
Cell System Human myelogenous leukemia cell line (K562)
Exogenous Factor Acetaminophen Approved Drug
DT Modulation Acetaminophen induces the activity of ABCB1 [174]
Exogenous Factor Acetylcysteine Approved Drug
DT Modulation Acetylcysteine induces the activity of ABCB1 [175]
Exogenous Factor Aldosterone Approved Drug
DT Modulation Aldosterone induces the activity of ABCB1 [56], [26]
Exogenous Factor Artemisinin Approved Drug
DT Modulation Artemisinin induces the activity of ABCB1 [176]
Exogenous Factor Betamethasone Approved Drug
DT Modulation Betamethasone induces the activity of ABCB1 [177]
Exogenous Factor Brilinta Approved Drug
DT Modulation Brilinta inhibits the activity of ABCB1 [178]
Exogenous Factor Budesonide Approved Drug
DT Modulation Budesonide induces the activity of ABCB1 [179]
Exogenous Factor Canagliflozin Approved Drug
DT Modulation Canagliflozin inhibits the activity of ABCB1 [178]
Exogenous Factor Captopril Approved Drug
DT Modulation Captopril inhibits the activity of ABCB1 [110]
Exogenous Factor Celecoxib Approved Drug
DT Modulation Celecoxib inhibits the activity of ABCB1 [180], [181]
Exogenous Factor Chenodeoxycholic acid Approved Drug
DT Modulation Chenodeoxycholic acid induces the activity of ABCB1 [182]
Exogenous Factor Cisplatin Approved Drug
DT Modulation Cisplatin induces the activity of ABCB1 [183], [184]
Exogenous Factor Conivaptan Approved Drug
DT Modulation Conivaptan inhibits the activity of ABCB1 [110]
Exogenous Factor Daclatasvir Approved Drug
DT Modulation Daclatasvir inhibits the activity of ABCB1 [110]
Exogenous Factor Dacomitinib Approved Drug
DT Modulation Dacomitinib inhibits the activity of ABCB1 [185]
Exogenous Factor Dactinomycin Approved Drug
DT Modulation Dactinomycin induces the activity of ABCB1 [186]
Exogenous Factor Daunorubicin Approved Drug
DT Modulation Daunorubicin induces the activity of ABCB1 [187]
Exogenous Factor Diclofenac Approved Drug
DT Modulation Diclofenac induces the activity of ABCB1 [188]
Exogenous Factor Diltiazem Approved Drug
DT Modulation Diltiazem inhibits the activity of ABCB1 [189]
Exogenous Factor Dimethyl sulfoxide Approved Drug
DT Modulation Dimethyl sulfoxide induces the activity of ABCB1 [190]
Exogenous Factor Dinoprostone Approved Drug
DT Modulation Dinoprostone induces the activity of ABCB1 [180]
Exogenous Factor Docetaxel Approved Drug
DT Modulation Docetaxel induces the activity of ABCB1 [191]
Exogenous Factor Donepezil Approved Drug
DT Modulation Donepezil inhibits the activity of ABCB1 [192]
Exogenous Factor Eetuximab Approved Drug
DT Modulation Eetuximab induces the activity of ABCB1 [193]
Exogenous Factor Eliglustat Approved Drug
DT Modulation Eliglustat inhibits the activity of ABCB1 [110]
Exogenous Factor Epirubicin Approved Drug
DT Modulation Epirubicin induces the activity of ABCB1 [194], [195]
Exogenous Factor Etravirine Approved Drug
DT Modulation Etravirine inhibits the activity of ABCB1 [110]
Exogenous Factor Everolimus Approved Drug
DT Modulation Everolimus inhibits the activity of ABCB1 [110]
Exogenous Factor Fenbufen Approved Drug
DT Modulation Fenbufen induces the activity of ABCB1 [188]
Exogenous Factor Fidaxomicin Approved Drug
DT Modulation Fidaxomicin inhibits the activity of ABCB1 [178]
Exogenous Factor Flibanserin Approved Drug
DT Modulation Flibanserin inhibits the activity of ABCB1 [110]
Exogenous Factor Flucloxacillin Approved Drug
DT Modulation Flucloxacillin induces the activity of ABCB1 [196]
Exogenous Factor Fluorouracil Approved Drug
DT Modulation Fluorouracil induces the activity of ABCB1 [197]
Exogenous Factor Fluoxetine Approved Drug
DT Modulation Fluoxetine inhibits the activity of ABCB1 [178]
Exogenous Factor Fosamprenavir Approved Drug
DT Modulation Fosamprenavir induces the activity of ABCB1 [110]
Exogenous Factor Fosphenytoin Approved Drug
DT Modulation Fosphenytoin induces the activity of ABCB1 [198]
Exogenous Factor Glecaprevir Approved Drug
DT Modulation Glecaprevir inhibits the activity of ABCB1 [199]
Exogenous Factor Hydroxyurea Approved Drug
DT Modulation Hydroxyurea induces the activity of ABCB1 [200]
Exogenous Factor Insulin Approved Drug
DT Modulation Insulin inhibits the activity of ABCB1 [201]
Exogenous Factor Isradipine Approved Drug
DT Modulation Isradipine inhibits the activity of ABCB1 [110]
Exogenous Factor Ivacaftor Approved Drug
DT Modulation Ivacaftor inhibits the activity of ABCB1 [110]
Exogenous Factor Lapatinib Approved Drug
DT Modulation Lapatinib inhibits the activity of ABCB1 [110]
Exogenous Factor Ledipasvir Approved Drug
DT Modulation Ledipasvir inhibits the activity of ABCB1 [110]
Exogenous Factor Lomitapide Approved Drug
DT Modulation Lomitapide inhibits the activity of ABCB1 [110]
Exogenous Factor Metformin Approved Drug
DT Modulation Metformin inhibits the activity of ABCB1 [202]
Exogenous Factor Micafungin Approved Drug
DT Modulation Micafungin inhibits the activity of ABCB1 [203]
Exogenous Factor Midazolam Approved Drug
DT Modulation Midazolam induces the activity of ABCB1 [75]
Exogenous Factor Mirabegron Approved Drug
DT Modulation Mirabegron inhibits the activity of ABCB1 [178]
Exogenous Factor Mitoxantrone Approved Drug
DT Modulation Mitoxantrone induces the activity of ABCB1 [204]
Exogenous Factor Naproxen Approved Drug
DT Modulation Naproxen inhibits the activity of ABCB1 [110]
Exogenous Factor Nilotinib Approved Drug
DT Modulation Nilotinib inhibits the activity of ABCB1 [110]
Exogenous Factor Ouabain Approved Drug
DT Modulation Ouabain induces the activity of ABCB1 [205], [206]
Exogenous Factor Oxycodone Approved Drug
DT Modulation Oxycodone induces the activity of ABCB1 [207]
Exogenous Factor Oxytetracycline Approved Drug
DT Modulation Oxytetracycline induces the activity of ABCB1 [208]
Exogenous Factor Phenobarbital Approved Drug
DT Modulation Phenobarbital induces the activity of ABCB1 [75]
Exogenous Factor Phenytoin Approved Drug
DT Modulation Phenytoin induces the activity of ABCB1 [209]
Exogenous Factor Pibrentasvir Approved Drug
DT Modulation Pibrentasvir inhibits the activity of ABCB1 [110]
Exogenous Factor Posaconazole Approved Drug
DT Modulation Posaconazole inhibits the activity of ABCB1 [110]
Exogenous Factor Probenecid Approved Drug
DT Modulation Probenecid inhibits the activity of ABCB1 [210], [211]
Exogenous Factor Propafenone Approved Drug
DT Modulation Propafenone inhibits the activity of ABCB1 [110]
Exogenous Factor Ranolazine Approved Drug
DT Modulation Ranolazine inhibits the activity of ABCB1 [110]
Exogenous Factor Rescinnamine Approved Drug
DT Modulation Rescinnamine induces the activity of ABCB1 [212]
Exogenous Factor Rifaximin Approved Drug
DT Modulation Rifaximin inhibits the activity of ABCB1 [178]
Exogenous Factor Rolapitant Approved Drug
DT Modulation Rolapitant inhibits the activity of ABCB1 [110]
Exogenous Factor Saquinavir Approved Drug
DT Modulation Saquinavir induces the activity of ABCB1 [104], [213]
Exogenous Factor Sirolimus Approved Drug
DT Modulation Sirolimus induces the activity of ABCB1 [75]
Exogenous Factor Suvorexant Approved Drug
DT Modulation Suvorexant inhibits the activity of ABCB1 [178]
Exogenous Factor Tacrolimus Approved Drug
DT Modulation Tacrolimus induces the activity of ABCB1 [75]
Exogenous Factor Telmisartan Approved Drug
DT Modulation Telmisartan inhibits the activity of ABCB1 [110]
Exogenous Factor Ticagrelor Approved Drug
DT Modulation Ticagrelor inhibits the activity of ABCB1 [110]
Exogenous Factor Tolvaptan Approved Drug
DT Modulation Tolvaptan inhibits the activity of ABCB1 [178]
Exogenous Factor Trazodone Approved Drug
DT Modulation Trazodone induces the activity of ABCB1 [90]
Exogenous Factor Tretinoin Approved Drug
DT Modulation Tretinoin induces the activity of ABCB1 [214], [215]
Exogenous Factor Valproic Acid Approved Drug
DT Modulation Valproic Acid induces the activity of ABCB1 [216]
Exogenous Factor Vancomycin Approved Drug
DT Modulation Vancomycin inhibits the activity of ABCB1 [217]
Exogenous Factor Velpatasvir Approved Drug
DT Modulation Velpatasvir inhibits the activity of ABCB1 [110]
Exogenous Factor Vemurafenib Approved Drug
DT Modulation Vemurafenib inhibits the activity of ABCB1 [178]
Exogenous Factor Vincamine Approved Drug
DT Modulation Vincamine inhibits the activity of ABCB1 [218]
Exogenous Factor Vincristine Approved Drug
DT Modulation Vincristine induces the activity of ABCB1 [219], [220]
Exogenous Factor Vismodegib Approved Drug
DT Modulation Vismodegib inhibits the activity of ABCB1 [221]
Exogenous Factor Yohimbine Approved Drug
DT Modulation Yohimbine induces the activity of ABCB1 [212]
Exogenous Factor Asunaprevir Drug in Phase 3 Trial
DT Modulation Asunaprevir inhibits the activity of ABCB1 [178]
Exogenous Factor Elobixibat Drug in Phase 3 Trial
DT Modulation Elobixibat inhibits the activity of ABCB1 [178]
Exogenous Factor Epinephrine Drug in Preclinical Test
DT Modulation Epinephrine induces the activity of ABCB1 [222]
Exogenous Factor Isavuconazole Drug in Phase 3 Trial
DT Modulation Isavuconazole inhibits the activity of ABCB1 [110]
Exogenous Factor Quinidine Drug Withdrawn
DT Modulation Quinidine inhibits the activity of ABCB1 [110]
Exogenous Factor Trabectedin Drug in Phase 3 Trial
DT Modulation Trabectedin inhibits the activity of ABCB1 [223]
References
1 Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73.
2 PSC833, cyclosporin A, and dexniguldipine effects on cellular calcein retention and inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochem Biophys Res Commun. 1999 Apr 13;257(2):410-3.
3 Aureobasidins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC-transporter. J Med Chem. 2000 Jun 29;43(13):2547-56.
4 Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5.
5 Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.
6 In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos. 2006 May;34(5):786-92.
7 Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72.
8 Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res. 2003 Feb;20(2):161-8.
9 Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60.
10 Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein. Jpn J Cancer Res. 1998 Nov;89(11):1220-8.
11 The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. Cancer Res. 2001 Oct 15;61(20):7525-9.
12 Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. Mol Pharmacol. 1994 Apr;45(4):773-6.
13 4-Substituted-2-phenylquinazolines as inhibitors of BCRP. Bioorg Med Chem Lett. 2012 Nov 1;22(21):6766-9.
14 HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2). J Med Chem. 2015 May 14;58(9):3910-21.
15 P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch. 1999 Apr;437(5):652-60.
16 Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats. Eur J Pharmacol. 2004 Jan 26;484(2-3):333-9.
17 Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther. 2003 Nov;307(2):824-8.
18 Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther. 2000 Jan;292(1):310-8.
19 The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Release. 2004 Mar 24;95(3):447-53.
20 Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther. 1998 Sep;286(3):1439-45.
21 Ligand Promiscuity between the Efflux Pumps Human P-Glycoprotein and S. aureus NorA. ACS Med Chem Lett. 2012 Jan 23;3(3):248-51.
22 Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol. 2004 Dec;143(7):856-64.
23 Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe. Leukemia. 1997 Jul;11(7):1147-55.
24 C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump. J Med Chem. 2002 Jan 17;45(2):390-8.
25 A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6.
26 Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91.
27 Contribution of down-regulation of intestinal and hepatic cytochrome P450 3A to increased absorption of cyclosporine A in a rat nephrosis model. J Pharmacol Exp Ther. 2008 Nov;327(2):592-9.
28 Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm Res. 2004 Aug;21(8):1398-404.
29 Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos. 2002 Jul;30(7):763-70.
30 Differential effects of the optical isomers of KR30031 on cardiotoxicity and on multidrug resistance reversal activity. Anticancer Drugs. 2003 Feb;14(2):175-81.
31 Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7.
32 Bioactive tetrahydrofuran lignans from Peperomia dindygulensis. J Nat Prod. 2005 Nov;68(11):1656-60.
33 The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes. J Nat Prod. 2011 Apr 25;74(4):567-73.
34 Overcoming human P-glycoprotein-dependent multidrug resistance with novel dihydro--agarofuran sesquiterpenes. Eur J Med Chem. 2011 Oct;46(10):4915-23.
35 Synthesis and evaluation of nitric oxide-releasing DDB derivatives as potential Pgp-mediated MDR reversal agents in MCF-7/Adr cells. Bioorg Med Chem Lett. 2012 Jan 15;22(2):801-5.
36 Identification of serotonin 5-HT1A receptor partial agonists in ginger. Bioorg Med Chem. 2010 May 1;18(9):3345-51.
37 Synthesis and biological evaluation of novel bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potent P-glycoprotein inhibitors. Eur J Med Chem. 2012 May;51:137-44.
38 Exploration of 2-((Pyridin-4-ylmethyl)amino)nicotinamide Derivatives as Potent Reversal Agents against P-Glycoprotein-Mediated Multidrug Resistance. J Med Chem. 2017 Apr 13;60(7):2930-2943.
39 Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors. Bioorg Med Chem. 2017 Aug 1;25(15):4194-4202.
40 Amine linked flavonoid dimers as modulators for P-glycoprotein-based multidrug resistance: structure-activity relationship and mechanism of modulation. J Med Chem. 2012 Mar 8;55(5):1999-2014.
41 Evaluation of the first cytostatically active 1-aza-9-oxafluorenes as novel selective CDK1 inhibitors with P-glycoprotein modulating properties. J Med Chem. 2003 Feb 27;46(5):876-9.
42 Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems. Drug Metab Dispos. 2000 Oct;28(10):1238-43.
43 Interaction of cyclosporin derivatives with the ATPase activity of human P-glycoprotein. Br J Pharmacol. 1997 Sep;122(2):241-8.
44 Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46.
45 The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998 Jan 15;101(2):289-94.
46 Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem Pharmacol. 1997 Jan 10;53(1):17-25.
47 Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023. Cancer Chemother Pharmacol. 2004 May;53(5):363-9.
48 Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs. 1996 Jul;7(5):568-78.
49 Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur J Pharm Sci. 2006 Apr;27(5):543-54.
50 MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs. Biol Pharm Bull. 2002 Dec;25(12):1604-7.
51 Structure-activity relationships of dibenzoylhydrazines for the inhibition of P-glycoprotein-mediated quinidine transport. Bioorg Med Chem. 2016 Jul 15;24(14):3184-91.
52 Modular construction of quaternary hemiaminal-based inhibitor candidates and their in cellulo assessment with HIV-1 protease. Bioorg Med Chem. 2013 Sep 1;21(17):5407-13.
53 Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46.
54 HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res. 2001 Jun;18(6):800-6.
55 Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.
56 Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem. 1992 Dec 5;267(34):24248-52.
57 Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14.
58 Synthesis and antimultidrug resistance evaluation of icariin and its derivatives. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4237-40.
59 Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther. 2002 Aug;302(2):645-50.
60 Reversal of multidrug resistance by morning glory resin glycosides in human breast cancer cells. J Nat Prod. 2012 Jan 27;75(1):93-7.
61 Purgin II, a resin glycoside ester-type dimer and inhibitor of multidrug efflux pumps from Ipomoea purga. J Nat Prod. 2013 Jan 25;76(1):64-71.
62 Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002 Jan;71(1):11-20.
63 Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J Pharm Sci. 2007 Oct;96(10):2808-17.
64 Repeated dosing of piperine induced gene expression of P-glycoprotein via stimulated pregnane-X-receptor activity and altered pharmacokinetics of diltiazem in rats. Biopharm Drug Dispos. 2012 Nov;33(8):446-54.
65 Effect of piperine, a major component of black pepper, on the intestinal absorption of fexofenadine and its implication on food-drug interaction. J Food Sci. 2010 Apr;75(3):H93-6.
66 Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7.
67 Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res. 1999 Apr;16(4):478-85.
68 Piperine activates human pregnane X receptor to induce the expression of cytochrome P450 3A4 and multidrug resistance protein 1. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):96-107.
69 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
70 Isoniazid accumulation in Mycobacterium smegmatis is modulated by proton motive force-driven and ATP-dependent extrusion systems. Biochem Biophys Res Commun. 1999 Mar 24;256(3):682-4.
71 Molecular cloning and characterization of an ABC multidrug efflux pump, VcaM, in Non-O1 Vibrio cholerae. Antimicrob Agents Chemother. 2003 Aug;47(8):2413-7.
72 Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet. 2007;46(12):1039-49.
73 Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies. Mol Pharm. 2010 Apr 5;7(2):398-411.
74 Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion. Drug Metab Dispos. 2006 May;34(5):775-82.
75 Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8.
76 Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci. 2001 Nov;90(11):1829-37.
77 In vivo and in vitro modulation of MDR molecules in murine thymocytes. Int Immunopharmacol. 2006 Feb;6(2):204-15.
78 Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci. 2001 Feb;12(4):505-13.
79 Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol. 2001 Dec;14(12):1596-603.
80 Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65.
81 In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther. 2004 Jul-Aug;11(4):262-77.
82 Garlic flavonoids and organosulfur compounds: impact on the hepatic pharmacokinetics of saquinavir and darunavir. Drug Metab Pharmacokinet. 2010;25(6):521-30.
83 Aged garlic extract stimulates p-glycoprotein and multidrug resistance associated protein 2 mediated effluxes. Biol Pharm Bull. 2009 Apr;32(4):694-9.
84 Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. Eur J Pharm Sci. 2010 Dec 23;41(5):729-35.
85 Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression? Planta Med. 2006 Jun;72(8):685-90.
86 Interactions between antiparkinsonian drugs and ABCB1/P-glycoprotein at the blood-brain barrier in a rat brain endothelial cell model. Neurosci Lett. 2008 Sep 5;442(1):19-23.
87 Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin Pharmacol Ther. 2003 Jan;73(1):51-60.
88 Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm Res. 2000 Oct;17(10):1189-97.
89 In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol. 2008 May;102(5):466-75.
90 P-glycoprotein interactions of nefazodone and trazodone in cell culture. J Clin Pharmacol. 2001 Jul;41(7):708-14.
91 Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells. Biochem Pharmacol. 1995 May 11;49(9):1255-60.
92 Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother. 2007 Oct;51(10):3498-504.
93 Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
94 Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.
95 Pyronaridine, a novel modulator of P-glycoprotein-mediated multidrug resistance in tumor cells in vitro and in vivo. Biochem Biophys Res Commun. 2004 Jul 9;319(4):1124-31.
96 Carbamazepine: Watch for Many Potential Drug Interactions
97 Optimization of novel indole-2-carboxamide inhibitors of neurotropic alphavirus replication. J Med Chem. 2013 Nov 27;56(22):9222-41.
98 Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem Biophys Res Commun. 2005 Feb 18;327(3):866-70.
99 St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther. 2000 Dec;68(6):598-604.
100 Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity. PLoS One. 2015 Mar 17;10(3):e0119502.
101 Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro. Int J Antimicrob Agents. 2014 Feb;43(2):184-8.
102 Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204.
103 Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01201-17.
104 Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS. 2000 Jun 16;14(9):1287-9.
105 The effect of arsenic trioxide (As2O3) combined with BSO on K562/ADM cell and its mechanisms. Zhonghua Xue Ye Xue Za Zhi. 2007 Jul;28(7):438-43.
106 Down-regulation of ABCB1 transporter by atorvastatin in a human hepatoma cell line and in human peripheral blood mononuclear cells. Biochim Biophys Acta. 2006 Dec;1760(12):1866-73.
107 VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res. 2004 Mar 1;10(5):1826-34.
108 VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res. 2004 Mar 1;10(5):1826-34.
109 Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther. 2004 Sep;76(3):192-200.
110 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
111 Inhibition of cytarabine-induced MDR1 (P-glycoprotein) gene activation in human tumor cells by fatty acid-polyethylene glycol-fatty acid diesters, novel inhibitors of P-glycoprotein function. Int J Cancer. 1996 Oct 9;68(2):245-50.
112 Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil. Cancer Sci. 2003 Jan;94(1):81-6.
113 Expression and functional activity of P-glycoprotein in cultured hepatocytes from Oncorhynchus mykiss. Am J Physiol Regul Integr Comp Physiol. 2001 Oct;281(4):R1119-26.
114 Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1. Br J Cancer. 2007 Oct 22;97(8):1077-83.
115 Tamoxifen activates CYP3A4 and MDR1 genes through steroid and xenobiotic receptor in breast cancer cells. Endocrine. 2006 Dec;30(3):261-8.
116 Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions. Clin Pharmacokinet. 2013 Jul;52(7):487-510.
117 Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1. J Nat Prod. 2016 Aug 26;79(8):2135-42.
118 Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos. 2001 Aug;29(8):1080-3.
119 Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology. 2002 Apr;96(4):913-20.
120 Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2001 Dec;364(6):551-7.
121 Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity. Malar J. 2014 Sep 13;13:359.
122 Specific interactions of chloroacetanilide herbicides with human ABC transporter proteins. Toxicology. 2008 Jun 3;248(1):45-51.
123 Alteration of human hepatic drug transporter activity and expression by cigarette smoke condensate. Toxicology. 2016 Jul 1;363-364:58-71.
124 Regulation of hepatic drug transporter activity and expression by organochlorine pesticides. J Biochem Mol Toxicol. 2014 Mar;28(3):119-28.
125 Inhibition of human MDR1 and BCRP transporter ATPase activity by organochlorine and pyrethroid insecticides. J Biochem Mol Toxicol. 2013 Feb;27(2):157-64.
126 Interactions of pesticides with membrane drug transporters: implications for toxicokinetics and toxicity. Expert Opin Drug Metab Toxicol. 2018 Jul;14(7):739-752.
127 Pesticides and their binary combinations as P-glycoprotein inhibitors in NIH 3T3/MDR1 cells.Environ Toxicol Pharmacol. 2006 Nov;22(3):268-76.
128 Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay. J Pharmacol Exp Ther. 1999 Jan;288(1):348-57.
129 Inhibition of Human Drug Transporter Activities by the Pyrethroid Pesticides Allethrin and Tetramethrin. PLoS One. 2017 Jan 18;12(1):e0169480.
130 Increase in doxorubicin cytotoxicity by inhibition of P-glycoprotein activity with lomerizine. Biol Pharm Bull. 2001 May;24(5):555-7.
131 In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013 Feb;41(2):353-61.
132 Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500.
133 Capsaicin pretreatment enhanced the bioavailability of fexofenadine in rats by P-glycoprotein modulation: in vitro, in situ and in vivo evaluation. Drug Dev Ind Pharm. 2017 Jun;43(6):932-938.
134 Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83.
135 Miltirone Is a Dual Inhibitor of P-Glycoprotein and Cell Growth in Doxorubicin-Resistant HepG2 Cells. J Nat Prod. 2015 Sep 25;78(9):2266-75.
136 Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmacol Sin. 2005 Aug;26(8):1009-16.
137 Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from StJohn's wort ( Hypericum perforatum ). J Clin Psychopharmacol. 2002 Feb;22(1):46-54.
138 Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein. Bioorg Med Chem. 2012 Jan 1;20(1):346-55.
139 Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals. Cancer Chemother Pharmacol. 2008 Oct;62(5):867-73.
140 Fructose-induced metabolic syndrome decreases protein expression and activity of intestinal P-glycoprotein. Nutrition. 2015 Jun;31(6):871-6.
141 Echinacea purpurea and P-glycoprotein drug transport in Caco-2 cells. Phytother Res. 2009 Jan;23(1):86-91.
142 Elevation of P-glycoprotein function by a catechin in green tea. Biochem Biophys Res Commun. 2002 Sep 20;297(2):412-8.
143 The effect of polyoxyethylene polymers on the transport of ranitidine in Caco-2 cell monolayers. Int J Pharm. 2011 May 16;409(1-2):164-8.
144 Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg(3). Biochem Pharmacol. 2003 Jan 1;65(1):75-82.
145 Effects of dietary ingredients on function and expression of P-glycoprotein in human intestinal epithelial cells. Biol Pharm Bull. 2010;33(2):255-9.
146 Effect of Schisandra chinensis extract and Ginkgo biloba extract on the pharmacokinetics of talinolol in healthy volunteers. Xenobiotica. 2009 Mar;39(3):249-54.
147 Effects of dietary flavonoids on the transport of cimetidine via P-glycoprotein and cationic transporters in Caco-2 and LLC-PK1 cell models. Xenobiotica. 2008 Dec;38(12):1536-50.
148 The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein. Anticancer Drugs. 1998 Mar;9(3):255-61.
149 Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance. Cancer Res. 2004 Oct 1;64(19):7130-8.
150 Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir. Clin Pharmacokinet. 2016 Feb;55(2):197-208.
151 Clinical pharmacogenomics of carvedilol: the stereo-selective metabolism angle. Pharmacogenomics. 2018 Sep 1;19(14):1089-1093.
152 Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013 Oct;13(5):331-42.
153 Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein. Br J Pharmacol. 2012 Jul;166(5):1669-83.
154 Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin. Eur J Pharm Sci. 2012 Aug 15;46(5):484-91.
155 Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676-82.
156 Modulation of the function of P-glycoprotein by estramustine. J Natl Cancer Inst. 1994 May 4;86(9):723-5.
157 A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin. J Clin Pharmacol. 2008 Sep;48(9):1092-8.
158 Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies. J Med Chem. 2014 Jul 24;57(14):6116-27.
159 Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium. Clin Pharmacol Ther. 2013 Jul;94(1):113-25.
160 An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med. 2007 Jul;73(8):731-41.
161 Digoxin up-regulates MDR1 in human colon carcinoma Caco-2 cells. Biochem Biophys Res Commun. 2002 Mar 22;292(1):190-4.
162 Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneously down-regulates steroid xenobiotic receptor mRNA. Biochem Biophys Res Commun. 2003 Jun 20;306(1):116-20.
163 Thyroid hormone regulates the activity and expression of the peptide transporter PEPT1 in Caco-2 cells. Am J Physiol Gastrointest Liver Physiol. 2002 Apr;282(4):G617-23.
164 Calcitriol and Calcipotriol Modulate Transport Activity of ABC Transporters and Exhibit Selective Cytotoxicity in MRP1-overexpressing Cells. Drug Metab Dispos. 2018 Dec;46(12):1856-1866.
165 Bexarotene Promotes Cholesterol Efflux and Restricts Apical-to-Basolateral Transport of Amyloid- Peptides in an In Vitro Model of the Human Blood-Brain Barrier. J Alzheimers Dis. 2015;48(3):849-62.
166 Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem. 2007 Feb;296(1-2):85-95.
167 Modulation of P-glycoprotein ATPase activity by some phytoconstituents. Phytother Res. 2010 Mar;24(3):454-8.
168 Role of ATP-binding cassette (ABC) transporters in interactions between natural products and drugs. Curr Drug Metab. 2008 Dec;9(10):1010-8.
169 P-Glycoprotein inhibitory activity of lipophilic constituents of Echinacea pallida roots in a human proximal tubular cell line. Planta Med. 2008 Feb;74(3):264-6.
170 Berry anthocyanins and anthocyanidins exhibit distinct affinities for the efflux transporters BCRP and MDR1. Br J Pharmacol. 2009 Dec;158(8):1942-50.
171 Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng. Planta Med. 2003 Mar;69(3):235-40.
172 Hypomethylation agent decitabine restores drug sensitivity by depressing P-glycoprotein activity through MAPK signaling pathway. Mol Cell Biochem. 2017 Sep;433(1-2):141-148.
173 Combination of dihydromyricetin and ondansetron strengthens antiproliferative efficiency of adriamycin in K562/ADR through downregulation of SORCIN: A new strategy of inhibiting P-glycoprotein. J Cell Physiol. 2019 Apr;234(4):3685-3696.
174 Acetaminophen-induced stimulation of MDR1 expression and activity in rat intestine and in LS 174T human intestinal cell line. Biochem Pharmacol. 2011 Jan 15;81(2):244-50.
175 Up-regulation of P-glycoprotein expression by catalase via JNK activation in HepG2 cells. Redox Rep. 2006;11(4):173-8.
176 Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65.
177 ABC drug transporter and nuclear receptor expression in human cytotrophoblasts: influence of spontaneous syncytialization and induction by glucocorticoids. Placenta. 2012 Nov;33(11):927-32.
178 KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01622)
179 Effects of budesonide on P-glycoprotein expression in intestinal cell lines. Br J Pharmacol. 2007 Feb;150(3):361-8.
180 Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line. Cancer Chemother Pharmacol. 2010 Apr;65(5):903-11.
181 Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-independent manner. J Cell Biochem. 2009 Sep 1;108(1):181-94.
182 Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans. Clin Pharmacol Ther. 2006 May;79(5):449-60.
183 Interferon-alpha modulates resistance to cisplatin in three human hepatoma cell lines. J Gastroenterol. 1999 Jun;34(3):351-8.
184 Up-regulation of MDR1 function and expression by cisplatin in LLC-PK1 cells. Biol Pharm Bull. 2003 Feb;26(2):205-9.
185 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB11963)
186 Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res. 1991 Oct 1;51(19):5275-83.
187 Aromatic hydrocarbon receptor (AhR).AhR nuclear translocator- and p53-mediated induction of the murine multidrug resistance mdr1 gene by 3-methylcholanthrene and benzo(a)pyrene in hepatoma cells. J Biol Chem. 2001 Feb 16;276(7):4819-27.
188 Effects of nonsteroidal anti-inflammatory drugs on the expression and function of P-glycoprotein/MDR1 in Caco-2 cells. Drug Chem Toxicol. 2009;32(4):332-7.
189 Inhibition of MDR1 activity in vitro by a novel class of diltiazem analogues: toward new candidates. J Med Chem. 2009 Jan 22;52(2):259-66.
190 Effects of dimethyl sulfoxide on the gene induction of cytochrome P450 isoforms, UGT-dependent glucuronosyl transferase isoforms, and ABCB1 in primary culture of human hepatocytes. Biol Pharm Bull. 2003 Jul;26(7):1052-6.
191 Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer. 2010 Aug 10;103(4):560-6.
192 Investigating the binding interactions of the anti-Alzheimer's drug donepezil with CYP3A4 and P-glycoprotein. Bioorg Med Chem Lett. 2015 Jan 15;25(2):297-301.
193 Cetuximab Prevents Methotrexate-Induced Cytotoxicity in Vitro through Epidermal Growth Factor Dependent Regulation of Renal Drug Transporters. Mol Pharm. 2017 Jun 5;14(6):2147-2157.
194 Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line. Br J Cancer. 1995 May;71(5):931-6.
195 Cancer cell adaptation to chemotherapy. BMC Cancer. 2005 Jul 18;5:78.
196 Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin. Curr Drug Metab. 2006 Feb;7(2):119-26.
197 Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line. Br J Cancer. 1999 Feb;79(5-6):831-7.
198 KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01893)
199 Translation of in vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. J Pharmacol Exp Ther. 2019 Jun 5. pii: jpet.119.256966.
200 The human multidrug resistance 1 promoter has an element that responds to serum starvation. Biochem Biophys Res Commun. 1992 Mar 16;183(2):917-24.
201 Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis. 2008 Sep;29(9):1837-44.
202 Metformin inhibits P-glycoprotein expression via the NF-B pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol. 2011 Mar;162(5):1096-108.
203 Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP. Antimicrob Agents Chemother. 2016 May 23;60(6):3372-9.
204 Multidrug resistance gene expression in rodents and rodent hepatocytes treated with mitoxantrone. Biochem Pharmacol. 1996 Nov 8;52(9):1453-60.
205 Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells. Antimicrob Agents Chemother. 2007 Aug;51(8):2748-57.
206 Drug resistance induced by ouabain via the stimulation of MDR1 gene expression in human carcinomatous pulmonary cells. Cancer Res. 2001 Feb 15;61(4):1693-8.
207 Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats. J Pharm Sci. 2007 Sep;96(9):2494-506.
208 Toxic responses of swimming crab (Portunus trituberculatus) larvae exposed to environmentally realistic concentrations of oxytetracycline. Chemosphere. 2017 Apr;173:563-571.
209 Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers. Br J Clin Pharmacol. 2009 Aug;68(2):226-37.
210 Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin. PLoS One. 2011;6(5):e20123.
211 Multidrug resistance P-glycoprotein is not involved in cholesterol esterification. Biochem Biophys Res Commun. 2000 Dec 20;279(2):369-77.
212 A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line. Mol Pharmacol. 1995 Oct;48(4):682-9.
213 Multidrug resistance protein 1-mediated transport of saquinavir by microglia. Neuroreport. 2004 May 19;15(7):1183-6.
214 Retinoic acid and forskolin activate the human MDR1 gene promoter in differentiated neuroblasts. Prog Clin Biol Res. 1994;385:103-10.
215 Influence of drugs and nutrients on transporter gene expression levels in Caco-2 and LS180 intestinal epithelial cell lines. Pharm Res. 2003 Aug;20(8):1119-24.
216 Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos. 2007 Jul;35(7):1032-41.
217 JBP485 attenuates vancomycin-induced nephrotoxicity by regulating the expressions of organic anion transporter (Oat) 1, Oat3, organic cation transporter 2 (Oct2), multidrug resistance-associated protein 2 (Mrp2) and P-glycoprotein (P-gp) in rats. Toxicol Lett. 2018 Oct 1;295:195-204.
218 Characterization of functional activity of ABCB1 and ABCC1 proteins in eggs and embryonic cells of the sea urchin Echinometra lucunter. Biosci Rep. 2010 Mar 17;30(4):257-65.
219 The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem Biophys Res Commun. 1989 Dec 29;165(3):1415-21.
220 L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett. 2010 Feb 15;192(3):408-18.
221 Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol. 2013 Apr;88(4):265-72.
222 Adrenaline induces chemoresistance in HT-29 colon adenocarcinoma cells. Cancer Genet Cytogenet. 2009 Apr 15;190(2):81-7.
223 Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6775-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.